Uric acid

Uric Acid (2,6,8-Trioxypurine, 2,6,8-Trihydroxypurine, 2,6,8-Trioxopurine), a normal component of urine, is a product of the metabolic breakdown of purine nucleotides.

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1g

￥537.00

430.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajce51896
CAS: 69-93-2
别名: 尿酸
分子式: C5H4N4O3
分子量: 168.11
纯度: >98%
溶解度: DMSO : < 1 mg/mL (insoluble or slightly soluble);Water : < 0.1 mg/mL (insoluble)
储存: Store at -20°C
库存: 现货

Background

Uric Acid (2,6,8-Trioxypurine, 2,6,8-Trihydroxypurine, 2,6,8-Trioxopurine), a normal component of urine, is a product of the metabolic breakdown of purine nucleotides.

Uric acid activates NFκB in a variety of cell culture models including proximal tubular cells. Uric acid suppresses 1-α hydroxylase mRNA and protein expression in dose dependent and time dependent manner[1].

Uric acid is synthesized mainly in the liver, intestines and the vascular endothelium as the end product of an exogenous pool of purines, and endogenously from damaged, dying and dead cells, whereby nucleic acids, adenine and guanine, are degraded into uric acid. Uric acid is a strong reactive oxygen species (ROS) and peroxynitrite scavenger and antioxidant. Uric acid may exert fundamental roles in tissue healing via initiating the inflammatory process that is necessary for tissue repair, scavenging oxygen free radicals, and mobilizing progenitor endothelial cells[2].

[1] Chen W, et al. Metabolism. 2014, 63(1):150-60. [2] Rashika El Ridi, et al. J Adv Res. 2017, 8(5): 487-493.

Protocol

Cell experiment:

Human colon carcinoma cells (Caco-2) are used and grown in Eagle’s minimum essential medium supplemented with 10% FBS, 1% non-essential amino acid mixture, and 1% Pen-Strep at 37°C in a humidified atmosphere with 5% CO2. Caco-2 cells are incubated with indomethacin in the presence or absence of Uric acid for 24 or 48 hours[1].

Animal experiment:

To evaluate the effect of oral administration of Uric acid on NSAID-induced enteropathy, mice are given Uric acid (2.5, 10, 25, 100, or 250 mg/kg body weight) suspended in 0.5% carboxymethyl cellulose orally at 30 minutes before, and 12 hours after indomethacin or vehicle treatment. To evaluate the effect of intraperitoneal administration of inosinic acid plus potassium oxonate on NSAID-induced enteropathy, mice are given inosinic acid (500 mg/kg body weight) plus potassium oxonate (250 mg/kg body weight) 24 intraperitoneally at 30 minutes before, and 12 hours after indomethacin or vehicle treatment[1].

参考文献:

[1]. Yasutake Y, et al. Uric acid ameliorates indomethacin-induced enteropathy in mice through its antioxidant activity. J Gastroenterol Hepatol. 2017 Nov;32(11):1839-1845.